Edgewise Therapeutics, Inc.
EWTX
$14.60
$0.302.10%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 35.63M | 34.01M | 31.87M | 28.87M | 26.33M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 174.54M | 170.04M | 158.83M | 147.15M | 136.17M |
Operating Income | -174.54M | -170.04M | -158.83M | -147.15M | -136.17M |
Income Before Tax | -150.70M | -146.09M | -133.81M | -124.29M | -115.88M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -150.70 | -146.09 | -133.81 | -124.29 | -115.88 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -150.70M | -146.09M | -133.81M | -124.29M | -115.88M |
EBIT | -174.54M | -170.04M | -158.83M | -147.15M | -136.17M |
EBITDA | -172.39M | -167.93M | -156.76M | -145.18M | -134.29M |
EPS Basic | -1.56 | -1.55 | -1.45 | -1.49 | -1.53 |
Normalized Basic EPS | -0.97 | -0.97 | -0.90 | -0.93 | -0.96 |
EPS Diluted | -1.56 | -1.55 | -1.45 | -1.49 | -1.53 |
Normalized Diluted EPS | -0.97 | -0.97 | -0.90 | -0.93 | -0.96 |
Average Basic Shares Outstanding | 388.61M | 377.18M | 369.62M | 339.67M | 309.32M |
Average Diluted Shares Outstanding | 388.61M | 377.18M | 369.62M | 339.67M | 309.32M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |